Three stocks from emerging Asia, a region racing ahead of its rivals
Emerging Asia should be the fastest-growing region in the world this year, says Avo Ora of the Pictet Asian Equities ex-Japan fund. Here, he picks three of his favourite stocks.
Emerging Asia has pulled out of the pandemic faster than many might have expected. Its outperformance relative to developed economies and emerging market peers is due to several factors. Its experience of dealing with past health crises – notably Sars – has allowed it to cope better with Covid-19.
What’s more, the bloc’s anti-crisis economic policies have been prudent and measured, in contrast to the West, where governments and central banks have been forced to take far more extreme measures.
Take China. Although it was at the epicentre of the pandemic, policymakers there have not had to resort to excessive fiscal or monetary largesse. The world’s second-largest economy has not experienced a build-up in borrowing on the scale of developed economies. For instance, it went into the crisis with public debt at less than 50% of GDP.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The picture is similar in the rest of emerging Asia, comparing favourably with G5-economies where the average debt-to-GDP ratio is expected to exceed 150% next year. Asia has managed to support growth without sowing the seeds of potential future financial shocks.
The economies of the regional heavyweights – China and India – are as diversified as the US, with a balanced mix of heavy industry and services sectors. Emerging Asia should be the fastest-growing region in the world this year, with GDP expanding by up to 8.6%. All of this throws up a number of attractive structural and cyclical investment opportunities.
One of these is Chailease International Finance Corp. (Taipei: 5871), a Taiwan-listed specialised-finance company that lends to consumers and small businesses. A market leader on its home turf, it is now successfully applying its expertise to the underpenetrated mainland Chinese market. Unlike some industries where economies of scale can make or break a company, this is an arena where being a smaller operator is a competitive advantage. This is because many of its customers are just too small for its larger peers to bother with, meaning it can pick a high-quality client base.
Another of our favourites is Ming Yang Smart Energy Group (Shanghai: 601615), a wind-turbine manufacturer. We believe the company will benefit from China’s 2060 carbon-neutral goal and the broader environmental aims set out in the country’s most recent five-year plan. This is a fragmented yet dynamic market that we believe should consolidate over time. It bodes well that Ming Yang is based in one of China’s richest provinces, which has both the intention and the capacity to spend money on more wind-turbine installations. While highly sought-after sectors such as renewables have frothy valuations, this is a well-priced company.
Finally, Wiwynn (Taipei: 6669) remains a core holding for us. It focuses on research and development as well as the distribution of servers for cloud services and hyperscale data centres. Demand for Wiwynn’s services is expected to grow as the world extends its move online and as the likes of Amazon and Facebook continue to build their servers and data centres. This stock has lagged its peers, but we remain impressed with the company’s structural growth potential as demand ramps up.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Avo Ora is manager of the Pictet Asian Equities ex-Japan fund
-
Lloyds axes foreign currency fees for Club Lloyds customers
Club Lloyds customers will be able to withdraw their money abroad without incurring any extra fees
By Daniel Hilton
-
How to invest during stagflation
Trump’s tariffs look poised to push the global economy into a period of stagflation. We look at how to ensure your investments can survive a global slowdown.
By Dan McEvoy
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Chemring Group: an explosive investment opportunity in defence
European states are raising their military spending, and Chemring Group looks well placed to profit
By Rupert Hargreaves
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves